Scientists Identify Four Stable Immune Personality Types in Healthy Adults
A 2-year study of 100 healthy adults reveals four distinct, stable immunotypes shaped by innate immune activity—not just age, sex, or CMV status.
Summary
Researchers at Benaroya Research Institute tracked 100 healthy adults aged 25–35 and 55–65 over two years, taking 10 blood samples each. Using mass cytometry, RNA sequencing, and protein profiling, they identified four distinct 'immunotypes'—stable immune personalities that remained consistent within individuals over time. These immunotypes differed in T cell composition, innate immune responsiveness, and inflammatory markers. Notably, they were not fully explained by age, sex, or cytomegalovirus infection status. One immunotype showed exaggerated CMV-related immune signatures plus reduced B cells. Another, found in young females, displayed unusually high inflammatory responses to bacterial signals. Immunotype strongly predicted responses to immune stimulation but not to flu vaccination, suggesting innate rather than adaptive immune variation is the key distinguishing feature.
Detailed Summary
Understanding why immune systems differ between healthy people is foundational to predicting who is at risk for autoimmune disease, cancer, or poor vaccine responses. Most prior research focused on single variables like age or infection history, missing the broader picture of individual immune identity.
This study from the BRI Sound Life Project comprehensively profiled 100 healthy adults across two age groups—25 to 35 and 55 to 65 years—over two years with 10 longitudinal visits. The team applied mass cytometry to map immune cell populations in detail, complemented by whole-blood RNA sequencing and Olink proteomic profiling to capture molecular signatures.
Four immunotypes emerged that were stable within individuals over the entire two-year period but meaningfully distinct between people. While known immune modulators like cytomegalovirus seropositivity, biological sex, and age did influence immune profiles, they did not fully account for the four immunotype groupings. One immunotype featured amplified CMV-associated markers alongside unexpected reductions in B cells and B cell-related gene expression. A particularly striking immunotype comprised young women with elevated innate immune reactivity, higher mature neutrophil counts, and increased systemic inflammatory markers.
Importantly, immunotype strongly predicted how individuals responded to ex vivo stimulation with lipopolysaccharide—a proxy for bacterial infection—but did not predict antibody responses to influenza vaccination. This suggests immunotypes primarily capture variation in innate immune tone rather than adaptive immune capacity.
These findings establish a framework for understanding baseline immune diversity in healthy populations. Identifying an individual's immunotype could one day help clinicians stratify disease risk, personalize vaccination strategies, or interpret inflammatory biomarkers more accurately. However, since the study is observational and limited to a relatively narrow age range, broader validation is needed before clinical application.
Key Findings
- Four stable immunotypes identified in healthy adults, remaining consistent within individuals over 2 years.
- Immunotypes were not solely determined by age, sex, or CMV infection status.
- A CMV-dominant immunotype showed unexpectedly reduced B cells beyond typical CMV immune effects.
- Young females in one immunotype had unusually high LPS responsiveness and elevated inflammatory markers.
- Immunotype predicted innate immune reactivity but not antibody response to influenza vaccination.
Methodology
A longitudinal cohort of 100 healthy adults (ages 25–35 and 55–65) was sampled 10 times over 2 years. Immune profiling used mass cytometry, whole-blood RNA sequencing, Olink proteomics, and ex vivo stimulation assays. Immunotypes were derived from immune cell populations stable within individuals across visits.
Study Limitations
The study enrolled only 100 participants within two relatively narrow age windows, limiting generalizability across the full adult lifespan. Observational design prevents causal conclusions about what drives immunotype assignment. Longer follow-up and larger, more diverse cohorts are needed to validate clinical utility.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.